Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology.
暂无分享,去创建一个
Stefan Tenzer | Katharina Landfester | Jörg Kuharev | Michael Maskos | Christoph Reinhardt | Verena Fetz | S. Tenzer | H. Schild | K. Landfester | Jörg Kuharev | M. Maskos | R. Stauber | D. Fischer | S. Knauer | F. Schlenk | A. Musyanovych | D. Docter | C. Reinhardt | Dominic Docter | Hansjörg Schild | Dagmar Fischer | V. Fetz | Rouven Hecht | K. Kiouptsi | Shirley K Knauer | Roland H Stauber | Anna Musyanovych | Florian Schlenk | Rouven Hecht | Klytaimnistra Kiouptsi
[1] Parag Aggarwal,et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.
[2] Iseult Lynch,et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.
[3] Mahesh Kumar Teli,et al. Nanotechnology and nanomedicine: going small means aiming big. , 2010, Current pharmaceutical design.
[4] Robert B Sim,et al. Surface properties: Immune attack on nanoparticles. , 2011, Nature nanotechnology.
[5] V. Rasche,et al. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. , 2010, Biomaterials.
[6] Ronald J. Moore,et al. Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size , 2011, Proteomics.
[7] Luigi Calzolai,et al. Protein--nanoparticle interaction: identification of the ubiquitin--gold nanoparticle interaction site. , 2010, Nano letters.
[8] Mauro Ferrari,et al. Nanomedicine—Challenge and Perspectives , 2009 .
[9] E. Vogler,et al. Protein adsorption in three dimensions. , 2012, Biomaterials.
[10] S. Tenzer,et al. Proteome-wide characterization of the RNA-binding protein RALY-interactome using the in vivo-biotinylation-pulldown-quant (iBioPQ) approach. , 2013, Journal of proteome research.
[11] S. Loibl,et al. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. , 2008, Cancer research.
[12] Iseult Lynch,et al. What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.
[13] L. Vroman,et al. Effect of Adsorbed Proteins on the Wettability of Hydrophilic and Hydrophobic Solids , 1962, Nature.
[14] Kevin Braeckmans,et al. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. , 2013, ACS nano.
[15] B. Wollenberg,et al. Functional Characterization of Novel Mutations Affecting Survivin (BIRC5)‐Mediated Therapy Resistance in Head and Neck Cancer Patients , 2013, Human mutation.
[16] Kenneth A. Dawson,et al. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. , 2012, ACS nano.
[17] Stefan Tenzer,et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. , 2011, ACS nano.
[18] D. Begley,et al. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain , 2010, Journal of drug targeting.
[19] Suchi Smita,et al. Nanoparticles in the environment: assessment using the causal diagram approach , 2012, Environmental Health.
[20] Marina A Dobrovolskaia,et al. Evaluation of nanoparticle immunotoxicity. , 2009, Nature nanotechnology.
[21] Philip M. Kelly,et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.
[22] Jim E Riviere,et al. An index for characterization of nanomaterials in biological systems. , 2010, Nature nanotechnology.
[23] Bengt Fadeel,et al. Safety assessment of nanomaterials: implications for nanomedicine. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[24] Katharina Landfester,et al. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. , 2011, ACS nano.
[25] U. Schubert,et al. Poly(2-ethyl-2-oxazoline) as alternative for the stealth polymer poly(ethylene glycol): comparison of in vitro cytotoxicity and hemocompatibility. , 2012, Macromolecular bioscience.
[26] Sara Linse,et al. Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.
[27] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[28] F. Bäckhed,et al. Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling , 2012, Nature.
[29] I. Schousboe,et al. High molecular weight kininogen binds to laminin – characterization and kinetic analysis , 2009, The FEBS journal.
[30] W. Peukert,et al. Impact of the nanoparticle-protein corona on colloidal stability and protein structure. , 2012, Langmuir : the ACS journal of surfaces and colloids.
[31] W. Meier,et al. Probing bioinspired transport of nanoparticles into polymersomes. , 2012, Angewandte Chemie.
[32] R. Jain,et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.
[33] R. Minchin,et al. Nanomedicine: sizing up targets with nanoparticles. , 2008, Nature nanotechnology.
[34] S Moein Moghimi,et al. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. , 2010, ACS nano.
[35] Albert Duschl,et al. Time evolution of the nanoparticle protein corona. , 2010, ACS nano.
[36] M. R. Anoop,et al. The present and future , 2001 .
[37] C. Ottmann,et al. Allosteric inhibition of Taspase1′s pathobiological activity by enforced dimerization in vivo , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] D. Begley,et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[39] Iseult Lynch,et al. The evolution of the protein corona around nanoparticles: a test study. , 2011, ACS nano.
[40] Kenneth A. Dawson,et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.
[41] Kenneth A. Dawson,et al. Nanobiotechnology: nanoparticle coronas take shape. , 2011, Nature nanotechnology.
[42] G. Oberdörster,et al. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology , 2010, Journal of internal medicine.
[43] Sara Linse,et al. Modeling the Time Evolution of the Nanoparticle-Protein Corona in a Body Fluid , 2010, PloS one.
[44] Colin R. Janssen,et al. Ecotoxicity and uptake of polymer coated gold nanoparticles , 2013, Nanotoxicology.
[45] Alison Elder,et al. Correlating physico-chemical with toxicological properties of nanoparticles: the present and the future. , 2010, ACS nano.
[46] Neetu Singh,et al. Nanoparticles that communicate in vivo to amplify tumour targeting. , 2011, Nature materials.
[47] Marco P Monopoli,et al. Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.
[48] Lutz Mädler,et al. Nanomaterials in the environment: from materials to high-throughput screening to organisms. , 2011, ACS nano.